13 completed, 2 withdrawn, 1 active not recruiting, 1 unknown. 17 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 13, Withdrawn 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Rotavirus Infections: new trials by email Literature Review of Rotavirus Infections trials Research Report on Rotavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Clinical Trial of the Inactivated Rotavirus Vaccine IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0, 28 - Rotavirus Infections, Diarrhea | Phase 2 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 600 | 2023-10-20 | 2024-01-03 |
| Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine, High dose Recombinant Trivalent Subunit Rotavirus Vaccine, Placebo - Rotavirus Infections, Rotavirus Gastroenteritis | Phase 2 | Active not recruiting | MAXVAX Biotechnology Limited Liability Company | 1512 | 2023-01-08 | 2024-11-20 |
| A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine RV3-BB, Placebo - Rotavirus Infections | Phase 2 | Completed | Murdoch Childrens Research Institute | 711 | 2018-06-15 | 2023-07-10 |
| Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine 251154 vaccine, Infanrix hexa™, Synflorix™ - Infections, Rotavirus | Phase 2 | Withdrawn | GlaxoSmithKline | 2010-04-01 | 2015-03-27 | |
| Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers RotaTeq, Placebo - HIV Infection, Rotavirus Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 202 | 2009-12-01 | 2021-11-05 |
| Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV], Placebo - Rotavirus Infections | Phase 1 / Phase 2 | Withdrawn | Shantha Biotechnics Limited | 240 | 2009-09-01 | 2010-02-03 |
| A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. Rotarix™, Placebo - Infections, Rotavirus, Rotavirus Vaccines | Phase 2 | Completed | GlaxoSmithKline | 375 | 2007-03-09 | 2020-01-02 |
| Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children Nitazoxanide - Rotavirus Infection, Viral Gastroenteritis Due to Rotavirus | Phase 2 | Completed | Romark Laboratories L.C. | 100 | 2005-12-01 | 2011-04-05 |
| Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis Live attenuated rotavirus vaccine - Infections, Rotavirus | Phase 2 | Completed | GlaxoSmithKline | 250 | 2005-08-01 | 2016-09-21 |
| A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh Rotavirus - Infections, Rotavirus | Phase 2 | Completed | GlaxoSmithKline | 300 | 2005-06-01 | 2016-09-21 |
| A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa Rotarix, Placebo, Tritanrix-HB+Hib - Infections, Rotavirus | Phase 2 | Completed | GlaxoSmithKline | 100 | 2005-03-16 | 2020-11-23 |
| Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children Alinia (nitazoxanide) - Rotavirus Infection, Adenoviridae Infection | Phase 2 / Phase 3 | Completed | Romark Laboratories L.C. | 50 | 2005-02-01 | 2012-05-31 |
| Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa HRV vaccine - Infections, Rotavirus | Phase 2 | Completed | GlaxoSmithKline | 472 | 2003-09-01 | 2016-09-15 |
| To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV Rotavirus (vaccine) - Rotavirus Infections | Phase 2 | Completed | GlaxoSmithKline | 450 | 2001-11-01 | 2016-09-09 |
| Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months HRV vaccine - Infections, Rotavirus | Phase 2 | Completed | GlaxoSmithKline | 2640 | 2001-05-31 | 2019-12-27 |
| Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants. Human Rotavirus Vaccine - two different formulations, Prevnar, IPOL - Infections, Rotavirus | Phase 2 | Completed | GlaxoSmithKline | 529 | 2000-11-01 | 2016-09-16 |
| Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants Rotarix - Infections, Rotavirus | Phase 2 | Completed | GlaxoSmithKline | 405 | 2000-08-01 | 2016-09-16 |
Gastroenteritis (4) · Adenoviridae Infections (1) · Caliciviridae Infections (1) · Diarrhea (1) · HIV Infections (1)
Infections (17) · RNA Virus Infections (17) · Reoviridae Infections (17) · Virus Diseases (17) · Digestive System Diseases (4) · Gastrointestinal Diseases (4) · Blood-Borne Infections (1) · Communicable Diseases (1) · DNA Virus Infections (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Lentivirus Infections (1) · Pathological Conditions, Signs and Symptoms (1) · Retroviridae Infections (1)
RIX4414 vaccine (4) · nitazoxanide (2) · Appointments and Schedules (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · PHiD-CV vaccine (1) · RotaTeq (1) · Rotavirus Vaccines (1) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1) · pentacel (1)
GlaxoSmithKline (10) · Romark Laboratories L.C. (2) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · MAXVAX Biotechnology Limited Liability Company (1) · Murdoch Childrens Research Institute (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Shantha Biotechnics Limited (1)
South Africa (3) · China (2) · Bangladesh (1) · Botswana (1) · Egypt (1) · Finland (1) · India (1) · Malawi (1) · Philippines (1) · Tanzania (1) · Zambia (1) · Zimbabwe (1)
Mona Abu-Zekry, MD (2) · Yanxia Wang (2) · Desiree Witte, MD MTropPaed (1) · Myron J. Levin, MD (1) · Raman Rao, MD (1)
PMID 16394298, PMID 16829296, PMID 21238572, PMID 27662551, PMID 39339964
2015 (2)